![FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial | DAIC FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial | DAIC](https://www.dicardiology.com/sites/default/files/styles/content_feed_large_new/public/Farxiga_1.jpeg?itok=kL1UUsf_)
FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial | DAIC
![Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/4bfbf57a-2a0c-4c38-a4ac-2719a7d372d1/cptclpt2008250-tbl-0001-m.jpg)
Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library
![Forxiga 10 Mg, Reduce Blood Glucose Level & Prevent Diabetes Complications - 28 Tablets | Al-Dawaa Pharmacies Forxiga 10 Mg, Reduce Blood Glucose Level & Prevent Diabetes Complications - 28 Tablets | Al-Dawaa Pharmacies](https://www.al-dawaa.com/media/catalog/product/cache/78f7fae576dd5c81f7109f594945761a/1/0/103072.jpg)
Forxiga 10 Mg, Reduce Blood Glucose Level & Prevent Diabetes Complications - 28 Tablets | Al-Dawaa Pharmacies
![Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects - Komoroski - 2009 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/98866967-cb17-4f5e-9d99-067f66b2f88e/cptclpt2008251-tbl-0001-m.jpg)